アジア太平洋地域のてんかん市場予測 2030 年 - 地域別分析 - タイプ別 (進行性ミオクロニーてんかん、反射性てんかん、全般てんかん、その他)、投与経路別 (経口、非経口、その他)、治療タイプ別 (第 1 世代の医薬品、第 2 世代の医薬品、第 3 世代の医薬品)、年齢層別 (成人および小児)、流通チャネル別 (病院薬局、小売薬局、その他)
組織による啓発プログラムの急増により、アジア太平洋地域のてんかん市場が拡大
てんかん、その症状、早期診断の重要性についての認識が高まるにつれて、医師の診察を求める患者が急増しています。てんかん財団、てんかん協会、米国てんかん協会、セントラルフロリダてんかん協会などの組織は、この病気について人々を教育する上で重要な役割を果たしています。これらの組織の関与により、診断率が向上し、てんかん治療を必要とする患者層が拡大しました。世界中の組織によって、この病気と利用可能な治療法に関する認識を広めるための啓発キャンペーンが数多く実施されています。 2023年のてんかんの日、インドのハイデラバードにあるアスタープライム病院は、クリシュナカントパークのウォーカーズ協会と共同で啓発活動を行いました。このセッションには、ウォーカーやヨガ愛好家など合計150人が参加しました。さらに、てんかんを患うオーストラリア人の生活の質を向上させるために、Epilepsy Action Australiaは、意識を高め、教育し、個人に必要なスキルを身につけさせることを目的としたさまざまなツールとサービスを提供しています。このように、このような取り組みや啓発キャンペーンは、てんかんの診断と治療の増加につながり、市場に有利な成長の機会を提供します。
アジア太平洋てんかん市場の概要
アジア太平洋てんかん市場は、中国、日本、インド、オーストラリア、韓国、およびその他のアジア太平洋地域に基づいて分析されています。世界保健機関（WHO）の報告書によると、てんかんは先進国よりも発展途上国で多く見られ、それぞれ6.1％と5.0％の有病率を占めています。
アジア太平洋地域のてんかん市場の収益と2030年までの予測（百万米ドル）
アジア太平洋地域のてんかん市場のセグメンテーション
アジア太平洋地域のてんかん市場は、タイプ、投与経路、治療タイプ、年齢層、流通チャネル、および国に分類されています。
タイプに基づいて、アジア太平洋地域のてんかん市場は、進行性ミオクロニーてんかん、反射てんかん、全般てんかん、その他に分類されています。全般てんかんセグメントは、2022年に最大の市場シェアを占めました。
投与経路に関しては、アジア太平洋地域のてんかん市場は、経口、非経口、その他に分類されています。 2022年には経口セグメントが最大の市場シェアを占めました。
治療タイプ別に見ると、アジア太平洋地域のてんかん市場は、第一世代の医薬品、第二世代の医薬品、第三世代の医薬品に分類されています。2022年には第三世代の医薬品セグメントが最大の市場シェアを占めました。
年齢層別に見ると、アジア太平洋地域のてんかん市場は成人と小児に分かれています。2022年には成人セグメントがより大きな市場シェアを占めました。
流通チャネル別に見ると、アジア太平洋地域のてんかん市場は、病院薬局、小売薬局、その他に分類されています。2022年には病院薬局セグメントが最大の市場シェアを占めました。
国別に見ると、アジア太平洋地域のてんかん市場は、中国、日本、インド、オーストラリア、韓国、その他のアジア太平洋地域に分類されています。 2022年、アジア太平洋地域のてんかん市場シェアは中国が独占しました。
アジア太平洋地域のてんかん市場で事業を展開している大手企業には、アボット ラボラトリーズ、ファイザー、エーザイ、UCB SA、リバノバ、ノバルティス、メドトロニック、GSK、H. ルンドベックなどがあります。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Asia Pacific Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Asia Pacific Analysis
6.1 Asia Pacific: Epilepsy Market
7. Asia Pacific Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Asia Pacific Epilepsy Market - Country Analysis
12.1 Asia Pacific Epilepsy Market Overview
12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 China: Epilepsy Market Overview
12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Japan: Epilepsy Market Overview
12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 India: Epilepsy Market Overview
12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Australia: Epilepsy Market Overview
12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 South Korea: Epilepsy Market Overview
12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Asia Pacific Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.